Genome Editing Tools: Beyond Discovery

It would seem that the fields of cell and molecular biology are steeped in irony. While we are taught about the inner workings of a single cell, we have only very recently begun to view the impact of an individual cell without lumping it into a common collective. For instance, advanced single-cell genomic techniques have allowed scientists to study disease from an entirely new perspective—a direction that is readily apparent within immunology research. As such, investigators are now able to look at individual T-cell phenotypes and begin to group them based on how they are immunologically primed.

The voyage of a cell or gene therapy from initial hypothesis to commercial delivery is complex and challenging. It requires a broad spectrum of scientific expertise, innovative technologies, and optimized processes to ensure these advanced therapeutics make it to market. In this GEN webinar, our panelists—two industry leaders—will discuss what it takes to develop a cell or gene therapy from concept to commercialization, alongside a conversation about innovations that are likely to shape the future of advanced therapy discovery and biomanufacturing.

In celebration of GEN’s 40th year in publishing, GEN Live will feature a panel of biotech reporters and scientists who have been covering the bioindustry since the early 1980s. Moreover, each wrote some of their initial biotech articles for GEN just as the industry, and GEN, was taking off.

While the importance of ligand-receptor binding kinetics on drug action is becoming well established, focus to date has been almost entirely on the role of the dissociation constant on drug efficacy and duration of action. The association rate constant, in contrast, has been largely overlooked, with many investigators still considering it diffusion-limited and equivalent across a compound series. This GEN webinar aims to remedy that by turning the spotlight onto the undervalued and oft-ignored association rate constant.